EGFR and glioblastoma: Additionally, an ongoing phase I study investigating bivalent CAR (targeting EGFR and IL13Rα2) engineered T cells recently reported transient reductions of recurrent glioblastoma, which has median overall survival of less than a year, in all treated patients (n=6) (12).